{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:48:21Z","timestamp":1793998101357,"version":"4.8.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"sup2","license":[{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"unspecified","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"company was provided with the opportunity to perform a medical accuracy review"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2020,10,16]]},"DOI":"10.1080\/00325481.2020.1798127","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T10:58:27Z","timestamp":1597921107000},"page":"26-36","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy"],"prefix":"10.1080","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-0496","authenticated-orcid":false,"given":"Eugene E.","family":"Wright Jr","sequence":"first","affiliation":[{"name":"Charlotte Area Health Education Center, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital; Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5951"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0120-z"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01606.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13185"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"cit0008","doi-asserted-by":"crossref","unstructured":"Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(S2):3\u201314.","DOI":"10.1080\/00325481.2020.1798099"},{"key":"cit0009","unstructured":"Ozempic\u00ae (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.443"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0424-2"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0428-y"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"cit0020","unstructured":"Rybelsus\u00ae (semaglutide) prescribing information\u00a0[updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213182s000,213051s001lbl.pdf"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"cit0022","unstructured":"Trulicity\u00ae (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf"},{"key":"cit0023","unstructured":"Victoza\u00ae (liraglutide) prescribing information [updated Jun 2019; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022341s031lbl.pdf"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0026","unstructured":"Byetta\u00ae (exenatide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021773s043lbl.pdf"},{"key":"cit0027","unstructured":"Bydureon\u00ae (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022200s030lbl.pdf"},{"key":"cit0028","unstructured":"Adlyxin\u00ae (lixisenatide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: http:\/\/products.sanofi.us\/Adlyxin\/Adlyxin.pdf"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14752"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"cit0031","doi-asserted-by":"crossref","unstructured":"Mosenzon O, Miller EM, Warren ML. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgrad Med. 2020;132(S2):37\u201347.","DOI":"10.1080\/00325481.2020.1800286"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"key":"cit0034","doi-asserted-by":"crossref","unstructured":"Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020;132(S2):15\u201325.","DOI":"10.1080\/00325481.2020.1798638"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13804"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12849"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0188"},{"key":"cit0039","doi-asserted-by":"crossref","unstructured":"Brunton SA, Mosenzon O, Wright EE. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020;132(S2):48\u201360.","DOI":"10.1080\/00325481.2020.1798162"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13172"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2017.01.943"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00706-y"},{"issue":"1","key":"cit0043","first-page":"1179","volume":"66","author":"B\u00e6kdal TA","year":"2017","journal-title":"Diabetes"},{"key":"cit0044","volume-title":"Presented at the American Diabetes Association","author":"Maarbjerg SJ","year":"2017"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0185"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0326-8"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.31.4.148"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1798127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T17:16:55Z","timestamp":1620580615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1798127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":50,"journal-issue":{"issue":"sup2","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["10.1080\/00325481.2020.1798127"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1798127","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}